name: Neuronal Ceroid Lipofuscinosis 3
category: Mendelian
creation_date: "2026-06-13T00:00:00Z"
description: >
  Neuronal ceroid lipofuscinosis 3 is a CLN3-related neuronal ceroid
  lipofuscinosis and the classic juvenile Batten disease branch. It usually
  presents in childhood with rapidly progressive visual failure from retinal
  degeneration, followed by cognitive and behavioral decline, seizures, motor
  deterioration, lysosomal fingerprint inclusions, and premature death. Current
  mechanistic evidence supports CLN3 as an endolysosomal membrane protein whose
  loss disrupts lysosomal trafficking, cholesterol handling, and storage biology.
disease_term:
  preferred_term: neuronal ceroid lipofuscinosis 3
  term:
    id: MONDO:0008767
    label: neuronal ceroid lipofuscinosis 3
synonyms:
- CLN3
- CLN3 disease
- neuronal ceroid lipofuscinosis type 3
- juvenile neuronal ceroid lipofuscinosis
- juvenile Batten disease
- Batten disease
parents:
- Neuronal Ceroid Lipofuscinosis
- Juvenile Neuronal Ceroid Lipofuscinosis
- Lysosomal Storage Disease
- Neurodegenerative Disease
classifications:
  lysosomal_storage_category:
    classification_value: neuronal ceroid lipofuscinosis
    notes: >-
      CLN3 disease is the classic juvenile neuronal ceroid lipofuscinosis, the
      most common of the Batten disease family, defined by lysosomal accumulation
      of autofluorescent ceroid lipopigment.
  icimd_category:
  - classification_value: neuronal_ceroid_lipofuscinosis
    notes: >-
      ICIMD places the neuronal ceroid lipofuscinoses among the disorders of
      complex molecule degradation (the classical lysosomal disorders); see
      classifications/icimd.yaml, where neuronal_ceroid_lipofuscinosis is
      declared is_a complex_molecule_degradation. No evidence item is attached
      because the available literature quotes support only the broader
      "CLN3 is a lysosomal storage disease" claim, not the ICIMD placement
      itself.
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
references:
- reference: PMID:20301601
  title: "Neuronal Ceroid Lipofuscinoses Overview."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:31926949
  title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
  findings:
  - statement: CLN3 causes juvenile NCL with early progressive visual loss.
  - statement: Vacuolated lymphocytes and lysosomal fingerprint inclusions support diagnosis.
- reference: PMID:37245481
  title: "Juvenile CLN3 disease is a lysosomal cholesterol storage disorder: similarities with Niemann-Pick type C disease."
  findings:
  - statement: CLN3 disease late endosome/lysosome fractions accumulate cholesterol.
- reference: PMID:36964447
  title: "Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging."
  findings:
  - statement: Confirmed CLN3 patients showed visual decline, retinal findings, and cognitive or motor features.
- reference: PMID:37113550
  title: "Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease)."
  findings:
  - statement: Behavioral symptoms such as mood disturbances and anxiety are common in JNCL/CLN3 disease.
- reference: PMID:37771451
  title: "Treatment of non-epileptic episodes of anxious, fearful behavior in adolescent juvenile neuronal ceroid lipofuscinosis (CLN3 disease)."
  findings:
  - statement: Recurrent non-epileptic frightened facial and body expression episodes occur in more than half of post-adolescent JNCL patients.
- reference: PMID:38500130
  title: "The parent and family impact of CLN3 disease: an observational survey-based study."
  findings:
  - statement: Insomnia and thought- and mood-related concerns are frequently reported in CLN3 caregiver surveys.
- reference: PMID:41501856
  title: "A timeline of symptom onset and disease progression in CLN3 disease."
  findings:
  - statement: A meta-analysis pooling nine CLN3 natural-history studies (423 patients) reports weighted mean ages at onset for 13 core symptoms.
  - statement: Vision loss is the earliest core symptom at 6.1 years, significantly younger than all other symptoms.
  - statement: Each per-symptom weighted mean derives from only one to four of the nine screened studies, with N ranging from 35 to 254.
inheritance:
- name: Autosomal recessive inheritance
  description: >
    CLN3 disease is inherited in an autosomal recessive pattern and is caused by
    biallelic pathogenic CLN3 variants.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: CGGV:assertion_6be652b4-092f-4d1c-9606-4dfeb689c4b9-2023-04-04T040000.000Z
    reference_title: "CLN3 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN3 | HGNC:2074 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >
      ClinGen classifies the CLN3-neuronal ceroid lipofuscinosis relationship
      as definitive with autosomal recessive inheritance.
progression:
- phase: Early visual onset
  age_range: 4 to 10 years
  notes: >
    Classic juvenile CLN3 typically starts with rapidly progressive visual loss
    from retinal degeneration. A meta-analysis screening nine natural-history
    studies (423 patients) puts the weighted mean age at onset of vision loss,
    pooled from four of those studies, at 6.1 (± 1.6) years (N = 254) —
    significantly younger than all other core symptoms in the pooled timeline
    (PMID:41501856).
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Presentation is typically in early childhood with vision loss at 4 to 10 years of age"
    explanation: >
      This CLN3 ocular phenotype paper summarizes the usual first clinical
      phase of juvenile CLN3 disease.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "From four studies, we calculated a weighted mean of 6.1 ± 1.6 years (N= 254), which was a significantly younger age than all other symptoms"
    explanation: >
      Data pooled from four of the screened natural-history studies (N = 254)
      confirm vision loss as the earliest and most tightly clustered core
      symptom onset in classic CLN3 disease.
- phase: Cognitive and behavioral decline
  age_range: 7 to 10 years
  notes: >
    Cognitive and behavioral dysfunction usually follows the visual decline,
    with anxiety, mood disturbance, and other atypical behaviors becoming
    clinically important. A pooled meta-analysis places the weighted mean age
    at onset of behavioural change at 8.5 (± 3.9) years (N = 194) and of
    cognitive decline at 9.3 (± 3.1) years (N = 219), consistent with this
    phase window (PMID:41501856).
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "behavioral and cognitive dysfunction at 7 to 10 years of age"
    explanation: >
      This supports the timing of neurobehavioral decline after visual onset.
  - reference: PMID:37113550
    reference_title: "Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "behavioral symptoms like mood disturbances and anxiety are common."
    explanation: >
      This review supports behavioral symptoms as part of the CLN3 disease
      trajectory.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "behavioural changes (8.5 ± 3.9,N= 194)"
    explanation: >
      Pooled natural-history data quantify the weighted mean age at onset of
      behavioural change, supporting the timing of this phase.
- phase: Motor decline and seizures
  age_range: 10 to 18 years
  notes: >
    Motor deterioration and seizures follow in later childhood. A pooled
    meta-analysis places the weighted mean age at onset of seizures at 10.2
    (± 3.0) years (N = 243) and of motor decline at 11.0 (± 3.8) years
    (N = 108) (PMID:41501856).
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive motor decline and seizures at 10 to 13 years of age, eventually leading to premature death in the second or third decade of life."
    explanation: >
      This supports the onset of the motor-decline and seizure phase at 10 to 13
      years in classic juvenile CLN3 disease. The mortality it describes is
      carried by the subsequent late multisystem decline phase.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which revealed an average age of onset for seizures of 10.2 ± 3.0 (N= 243) years"
    explanation: >
      Pooled natural-history data quantify the weighted mean age at onset of
      seizures, supporting the timing of this phase.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "motor decline (11.0 ± 3.8,N= 108)"
    explanation: >
      Pooled natural-history data quantify the weighted mean age at onset of
      motor decline, supporting the timing of this phase.
- phase: Late multisystem decline and mortality
  age_range: 18 years through the third decade
  notes: >
    Cardiac conduction abnormalities, loss of independent walking, and
    enteral-feeding dependence cluster in the late second and third decade,
    shortly before death. These pooled weighted mean ages at onset are: 17.8
    (± 4.4) years (N = 45) for cardiac manifestations, 19.5 (± 3.2) years
    (N = 70) for loss of independent walking, 22.0 (± 1.6) years (N = 35) for
    feeding difficulties requiring enteral feeding, and 22.4 (± 4.4) years
    (N = 95) for death. Cardiac manifestations and loss of independent walking
    occur at similar ages, but earlier than feeding difficulties and death,
    which occur together around 22 years. Life expectancy is reported as twenty
    to thirty years with a range of 20-39 years, so this phase is not bounded by
    the 22.4-year weighted mean age at death. These are weighted means pooled
    across heterogeneous studies, not a single prospective cohort: nine studies
    were screened into the meta-analysis, but each symptom's weighted mean
    derives from only one to four of them, and per-symptom N ranges from 35 to
    254 across the full 13-symptom timeline,
    so confidence is uneven, and the late milestones here (cardiac N = 45,
    enteral feeding N = 35) rest on especially small subsets. Ages are age at
    reported onset, so they inherit ascertainment and diagnostic-delay bias
    from the source cohorts (see PMID:31926949 on delayed diagnosis and
    ophthalmic masquerades).
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cardiac manifestations (17.8 ± 4.4,N= 45), loss of independent walking (19.5 ± 3.2,N= 70), feeding difficulties requiring enteral feeding tube (22.0 ± 1.6,N= 35), and death (22.4 ± 4.4,N= 95)"
    explanation: >
      Pooled natural-history data define the late-stage milestone sequence and
      weighted mean age at death in CLN3 disease. Each figure derives from a
      small subset of the nine screened studies: cardiac manifestations two
      (N = 45), loss of independent walking three (N = 70), feeding
      difficulties one (N = 35), and death two (N = 95).
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The life expectancy of people with classic CLN3 disease is twenty to thirty years"
    explanation: >
      Reported life expectancy extends through the third decade, supporting the
      upper bound of this phase beyond the 22.4-year weighted mean age at death.
prevalence:
- population: United States and several European countries
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.0
  notes: >-
    CLN3 disease birth incidence is approximately 1 per 100,000 live newborns in
    the United States and Germany.
  evidence:
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The incidence of CLN3-disease in the United States and several European
      countries (for example, Germany) is approximately 1 per 100,000 live
      newborns
    explanation: >-
      This review reports the ~1 per 100,000 live-newborn CLN3 disease birth
      incidence in the US and Europe.
- population: Finland (Scandinavia)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.0
  notes: >-
    JNCL reaches its highest prevalence in Scandinavia, with slightly more than
    1 in 25,000 live newborns in Finland (carrier frequency ~1 in 70),
    reflecting a founder mutation.
  evidence:
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The highest prevalence of JNCL is found in the Scandinavian countries,
      especially in Finland (slightly more than 1 in 25,000 live newborns with a
      carrier frequency of 1 in 70)
    explanation: >-
      This review reports the elevated Finnish JNCL birth prevalence (~1 in
      25,000) and 1-in-70 carrier frequency from a founder mutation.
genetic:
- name: CLN3
  association: Causal biallelic pathogenic variants
  presence: Positive
  gene_term:
    preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  notes: >
    CLN3 encodes an endolysosomal membrane protein. The common juvenile Batten
    allele is a roughly 1 kb deletion spanning exons 7 and 8, but additional
    pathogenic variants occur.
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is a form of NCL caused by sequence variants in the gene CLN3"
    explanation: >
      This human ocular phenotype series directly identifies CLN3 variants as
      the cause of juvenile Batten disease/JNCL.
biochemical:
- name: Mitochondrial ATP synthase subunit c storage
  presence: INCREASED
  context: >
    The characteristic storage material in CLN3 disease is subunit c of
    mitochondrial ATP synthase (SubC), which accumulates in lysosomes alongside
    other lipids. This lysosomal SubC storage is recapitulated in a human
    CLN3-knockout retinal pigment epithelial cell model.
  evidence:
  - reference: PMID:39080379
    reference_title: "TRPML1 activation ameliorates lysosomal phenotypes in CLN3 deficient retinal pigment epithelial cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      show lysosomal storage of mitochondrial ATPase subunit C (SubC),
      globotriaosylceramide (Gb3), and glycerophosphodiesters
    explanation: >
      A human CLN3-knockout RPE cell model shows lysosomal storage of
      mitochondrial ATP synthase subunit c, the classic NCL storage material.
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      one of the subunits of this enzyme (namely, C) accumulates in lysosomal
      inclusions, which is one of the distinctive signs of Batten disease
    explanation: >
      This CLN3/JNCL review identifies lysosomal accumulation of ATP synthase
      subunit c as a distinctive hallmark of Batten disease in patients,
      corroborating the cell-model finding.
- name: Vacuolated lymphocytes on peripheral blood film
  presence: PRESENT
  context: >
    Cytoplasmic vacuolation of circulating lymphocytes, visible by light
    microscopy on a routine peripheral blood film, is the classic and most
    accessible bedside screening marker for CLN3 disease. It is relatively
    specific to CLN3 among the neuronal ceroid lipofuscinoses and is
    accompanied by fingerprint lysosomal inclusions on ultrastructural study.
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vacuolated lymphocytes and lysosomal (fingerprint) inclusions on blood
      film
    explanation: >
      This detailed CLN3 patient study records vacuolated lymphocytes with
      fingerprint lysosomal inclusions on blood film as a diagnostic finding.
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "lymphocyte vacuoles in blood by light microscopy"
    explanation: >
      This CLN3/JNCL review confirms light-microscopic detection of lymphocyte
      vacuoles in blood as an accessible diagnostic step.
pathophysiology:
- name: CLN3 endolysosomal membrane dysfunction
  biological_scale: CELLULAR
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    CLN3 dysfunction perturbs endolysosomal membrane biology, lysosomal cargo
    handling, and cholesterol trafficking. The resulting lysosomal storage
    phenotype includes fingerprint inclusions in patient material and
    cholesterol accumulation in late endosome/lysosome fractions, contributing
    to progressive retinal and neuronal degeneration.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  biological_processes:
  - preferred_term: lysosomal transport
    modifier: DYSREGULATED
    term:
      id: GO:0007041
      label: lysosomal transport
  - preferred_term: cholesterol transport
    modifier: DYSREGULATED
    term:
      id: GO:0030301
      label: cholesterol transport
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood film microscopy revealed vacuolated lymphocytes, and electron microscopy showed lysosomal (fingerprint) inclusions in all 8 patients."
    explanation: >
      Human CLN3 cases show lysosomal storage inclusions, supporting
      conformance to lysosomal substrate accumulation.
  - reference: PMID:37245481
    reference_title: "Juvenile CLN3 disease is a lysosomal cholesterol storage disorder: similarities with Niemann-Pick type C disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "INTERPRETATION: Our results support that JNCL is a lysosomal cholesterol storage disorder."
    explanation: >
      Patient autopsy late endosome/lysosome data support lysosomal cholesterol
      storage as a CLN3 disease mechanism.
  downstream:
  - target: Lysosomal Cholesterol Storage
    description: >
      CLN3 disease late endosome/lysosome fractions accumulate cholesterol,
      supporting a cholesterol storage branch of the disease mechanism.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37245481
      reference_title: "Juvenile CLN3 disease is a lysosomal cholesterol storage disorder: similarities with Niemann-Pick type C disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "INTERPRETATION: Our results support that JNCL is a lysosomal cholesterol storage disorder."
      explanation: >
        Human autopsy material supports lysosomal cholesterol storage downstream
        of CLN3 dysfunction.
  - target: Progressive Retinal Degeneration
    description: >
      CLN3 endolysosomal dysfunction causes rapidly progressive retinal
      degeneration and visual failure.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31926949
      reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Participants presented with rapid bilateral vision loss over 1 to 18 months"
      explanation: >
        This supports retinal degeneration and visual failure as a downstream
        clinical consequence of CLN3 disease.
  - target: Progressive Neurobehavioral Decline
    description: >
      CLN3 disease progresses from cognitive and behavioral dysfunction to
      seizures, motor decline, and later severe neuropsychiatric/autonomic
      manifestations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31926949
      reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "behavioral and cognitive dysfunction at 7 to 10 years of age, and progressive motor decline and seizures at 10 to 13 years of age"
      explanation: >
        This summarizes the neurobehavioral and later neurologic progression of
        juvenile CLN3 disease.
- name: Lysosomal Cholesterol Storage
  biological_scale: CELLULAR
  description: >
    CLN3 disease late endosome/lysosome fractions accumulate cholesterol,
    supporting a lysosomal cholesterol storage mechanism that overlaps with
    other lipid-trafficking lysosomal disorders.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: cholesterol transport
    modifier: DYSREGULATED
    term:
      id: GO:0030301
      label: cholesterol transport
  evidence:
  - reference: PMID:37245481
    reference_title: "Juvenile CLN3 disease is a lysosomal cholesterol storage disorder: similarities with Niemann-Pick type C disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "INTERPRETATION: Our results support that JNCL is a lysosomal cholesterol storage disorder."
    explanation: >
      This patient autopsy study supports cholesterol storage as a distinct
      downstream CLN3 mechanism.
- name: Progressive Retinal Degeneration
  biological_scale: TISSUE
  description: >
    CLN3 disease causes early, rapidly progressive retinal degeneration with
    macular atrophy, outer retinal loss, electrophysiologic abnormalities, and
    visual failure.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Participants presented with rapid bilateral vision loss over 1 to 18 months"
    explanation: >
      Ocular cohort evidence supports rapid visual decline from retinal disease
      as a distinct CLN3 downstream branch.
- name: Progressive Neurobehavioral Decline
  biological_scale: ORGANISM
  description: >
    CLN3 disease progresses to cognitive impairment, behavioral symptoms,
    seizures, motor deterioration, sleep disruption, and advanced adolescent or
    adult neuropsychiatric/autonomic episodes.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "behavioral and cognitive dysfunction at 7 to 10 years of age, and progressive motor decline and seizures at 10 to 13 years of age"
    explanation: >
      This supports cognitive, behavioral, seizure, and motor progression as a
      downstream CLN3 disease branch.
  - reference: PMID:37771451
    reference_title: "Treatment of non-epileptic episodes of anxious, fearful behavior in adolescent juvenile neuronal ceroid lipofuscinosis (CLN3 disease)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recurrent non-epileptic episodes of frightened facial and body expression occur in more than half of post-adolescent patients with juvenile neuronal ceroid lipofuscinosis (JNCL, CLN3 disease)."
    explanation: >
      This supports advanced neurobehavioral/autonomic manifestations as part of
      CLN3 progression.
phenotypes:
- name: Visual impairment
  description: >
    Rapid visual decline is the usual first recognized manifestation of classic
    juvenile CLN3 disease, beginning in the great majority of patients.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
    onset:
      onset_category: JUVENILE
      mean_age_years: 6.1
      notes: >-
        Weighted mean age at onset pooled from four CLN3 natural-history
        studies (N = 254); earliest of the 13 core symptoms in the pooled
        timeline.
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Participants presented with rapid bilateral vision loss over 1 to 18 months"
    explanation: >
      This CLN3 ocular case series documents rapid bilateral vision loss in
      affected children.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vision loss (6.1 ± 1.6,N= 254)"
    explanation: >
      Weighted mean age at onset pooled from four of the nine natural-history
      cohorts screened into the meta-analysis (N = 254), supporting vision loss
      as the earliest core CLN3 symptom, significantly younger than all other
      symptoms.
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      in more than 80% of patients), the disease begins with a distinct
      functional visual impairment
    explanation: >
      This review supports visual impairment as the initial manifestation in
      more than 80% of patients, supporting the VERY_FREQUENT band.
- name: Retinal degeneration
  description: >
    CLN3 produces retinal degeneration with macular atrophy, outer retinal loss,
    and characteristic electrophysiologic or imaging abnormalities.
  phenotype_term:
    preferred_term: Retinal degeneration
    term:
      id: HP:0000546
      label: Retinal degeneration
  evidence:
  - reference: PMID:36964447
    reference_title: "Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CLN3 patients presented at median age 6.2 years with visual decline."
    explanation: >
      This genetically confirmed CLN3 ocular cohort supports early visual
      decline with retinal biomarker abnormalities.
- name: Cognitive impairment
  description: Cognitive or behavioral decline commonly follows or accompanies visual loss.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
    onset:
      onset_category: JUVENILE
      mean_age_years: 9.3
      notes: >-
        Weighted mean age at onset of cognitive decline pooled from the three
        CLN3 natural-history studies reporting mean and SD (N = 219).
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Six children displayed eccentric fixation, and 6 children had cognitive or neurologic signs at the time of diagnosis (75%)."
    explanation: >
      This cohort documents cognitive or neurologic signs at CLN3 diagnosis.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cognitive decline (9.3 ± 3.1,N= 219)"
    explanation: >
      Weighted mean age at onset pooled from the three natural-history cohorts
      reporting mean and SD (N = 219), supporting the timing of cognitive
      decline in CLN3 disease.
- name: Atypical behavior
  description: >
    Mood disturbance, anxiety, fearful episodes, and other behavioral symptoms
    are common during the CLN3 neurodegenerative course.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
    onset:
      onset_category: JUVENILE
      mean_age_years: 8.5
      notes: >-
        Weighted mean age at onset of behavioural change in the pooled CLN3
        natural-history dataset (N = 194); the paper does not state how many of
        the nine screened studies contributed to this pooled estimate.
  evidence:
  - reference: PMID:37113550
    reference_title: "Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "behavioral symptoms like mood disturbances and anxiety are common."
    explanation: >
      This supports behavior abnormalities within the CLN3/JNCL phenotype.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "behavioural changes (8.5 ± 3.9,N= 194)"
    explanation: >
      Pooled weighted mean age at onset (N = 194) supports the timing of
      behavioural change in CLN3 disease.
  - reference: PMID:37771451
    reference_title: "Treatment of non-epileptic episodes of anxious, fearful behavior in adolescent juvenile neuronal ceroid lipofuscinosis (CLN3 disease)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recurrent non-epileptic episodes of frightened facial and body expression occur in more than half of post-adolescent patients with juvenile neuronal ceroid lipofuscinosis (JNCL, CLN3 disease)."
    explanation: >
      This supports atypical fearful behavioral episodes in post-adolescent
      CLN3 disease.
- name: Sleep disturbance
  description: Insomnia and related sleep disruption are frequently reported by CLN3 caregivers.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
    onset:
      onset_category: JUVENILE
      mean_age_years: 11.0
      notes: >-
        Weighted mean age at onset reported by only one of the nine CLN3
        natural-history studies screened into the meta-analysis (N = 111), and
        carries a wide weighted SD (±6.1) relative to its mean, so its position
        in the timeline should not be over-read.
  evidence:
  - reference: PMID:38500130
    reference_title: "The parent and family impact of CLN3 disease: an observational survey-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Insomnia and thought- and mood-related concerns were reported frequently."
    explanation: >
      Parent/caregiver survey data support sleep disturbance, specifically
      insomnia, as a frequent CLN3-associated concern.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sleep disturbance (11.0 ± 6.1,N= 111)"
    explanation: >
      Pooled weighted mean age at onset from a single natural-history cohort
      contributing to the pooled analysis; note the wide standard deviation.
- name: Motor deterioration
  description: Progressive motor decline is part of the juvenile CLN3 trajectory.
  phenotype_term:
    preferred_term: Motor deterioration
    term:
      id: HP:0002333
      label: Motor deterioration
    onset:
      onset_category: JUVENILE
      mean_age_years: 11.0
      notes: >-
        Weighted mean age at onset of motor decline across two combined
        CLN3 natural-history studies (N = 108).
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Presentation is typically in early childhood with vision loss at 4 to 10 years of age, behavioral and cognitive dysfunction at 7 to 10 years of age, and progressive motor decline and seizures at 10 to 13 years of age"
    explanation: >
      This review text within the CLN3 ocular paper describes the typical
      timing of motor decline in juvenile CLN3 disease.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "motor decline (11.0 ± 3.8,N= 108)"
    explanation: >
      Pooled weighted mean age at onset from combined natural-history cohorts
      supports the timing of motor decline in CLN3 disease.
- name: Seizure
  description: Seizures are part of the later neurologic phase of juvenile CLN3 disease.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: JUVENILE
      mean_age_years: 10.2
      notes: >-
        Weighted mean age at onset across four combined CLN3 natural-history
        studies (N = 243).
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Presentation is typically in early childhood with vision loss at 4 to 10 years of age, behavioral and cognitive dysfunction at 7 to 10 years of age, and progressive motor decline and seizures at 10 to 13 years of age"
    explanation: >
      This source includes seizures as part of the typical CLN3 disease
      progression.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which revealed an average age of onset for seizures of 10.2 ± 3.0 (N= 243) years"
    explanation: >
      Pooled weighted mean age at onset from combined natural-history cohorts
      supports the timing of seizure onset in CLN3 disease.
- name: Abnormal electroretinogram
  description: >
    An electronegative electroretinogram (ERG) is a characteristic early ocular
    biomarker of CLN3 disease, reflecting inner retinal dysfunction.
  phenotype_term:
    preferred_term: Electronegative electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  evidence:
  - reference: PMID:36964447
    reference_title: "Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Electronegative ERGs were identified in all patients."
    explanation: >
      This genetically confirmed CLN3 cohort found an electronegative ERG in
      every patient.
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "electronegative ERG was present in 4 patients (50%), but with additional a-wave"
    explanation: >
      This ocular cohort documents electronegative ERGs as part of the CLN3
      retinal electrophysiologic phenotype.
- name: Bull's eye maculopathy
  description: >
    Bull's-eye maculopathy is a characteristic early fundus finding in CLN3
    disease, often present at ophthalmic presentation.
  phenotype_term:
    preferred_term: Bull's eye maculopathy
    term:
      id: HP:0011504
      label: Bull's eye maculopathy
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bilateral bull's-eye maculopathy at presentation"
    explanation: >
      This CLN3 ocular series documents bilateral bull's-eye maculopathy at
      presentation.
  - reference: PMID:36964447
    reference_title: "Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early onset maculopathy with an electronegative ERG and variable"
    explanation: >
      This genetically confirmed CLN3 cohort links early-onset maculopathy with
      the electronegative ERG signature.
- name: Parkinsonism
  description: >
    Extrapyramidal, Parkinson-like motor features emerge as the juvenile CLN3
    motor syndrome progresses.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
    onset:
      onset_category: JUVENILE
      mean_age_years: 14.1
      notes: >-
        Weighted mean age at onset of Parkinsonian gait reported by only one of
        the nine CLN3 natural-history studies screened into the meta-analysis
        (N = 111); the paper's own limitations name Parkinsonian gait alongside
        sleep disturbance and feeding difficulties as single-study symptoms, so
        its position in the timeline should not be over-read.
  evidence:
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "begins with Parkinson-like symptoms and leads to dementia"
    explanation: >
      This review describes the progressive CLN3 motor decline as beginning with
      Parkinson-like symptoms.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parkinsonian gait (14.1 ± 2.5,N= 111)"
    explanation: >
      Weighted mean age at onset from a single natural-history cohort (N = 111)
      supports the timing of Parkinsonian gait in CLN3 disease.
- name: Dementia
  description: >
    Progressive cognitive decline culminates in dementia in the later stages of
    juvenile CLN3 disease.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "begins with Parkinson-like symptoms and leads to dementia"
    explanation: >
      This review describes the progressive CLN3 neurodegenerative course as
      leading to dementia.
- name: Complete blindness
  description: >
    Progression from vision loss to complete blindness is a later, distinct
    milestone in the CLN3 visual-decline trajectory, reported separately from
    initial vision-loss onset by pooled natural-history studies.
  phenotype_term:
    preferred_term: Complete blindness
    term:
      id: HP:0000618
      label: Blindness
    onset:
      onset_category: JUVENILE
      mean_age_years: 11.4
      notes: >-
        Weighted mean age at onset across three combined CLN3 natural-history
        studies (N = 171); definitions of "complete" vision loss were not
        consistently applied across the source studies.
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complete blindness (11.4 ± 3.6,N= 171)"
    explanation: >
      Pooled weighted mean age at onset from three natural-history cohorts
      supports complete blindness as a distinct, later milestone following
      initial vision loss in CLN3 disease.
- name: Speech and language impairment
  description: >
    Speech clarity and verbal output deteriorate progressively in CLN3 disease,
    with dysarthria, word-finding difficulty, and dysfluency; expressive
    language is often relatively stronger than receptive language.
  phenotype_term:
    preferred_term: Speech and language impairment
    term:
      id: HP:0002463
      label: Language impairment
    onset:
      onset_category: JUVENILE
      mean_age_years: 12.7
      notes: >-
        Weighted mean age at onset across two combined CLN3 natural-history
        studies (N = 136).
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "speech and language impairment (12.7 ± 4.8,N= 136)"
    explanation: >
      Pooled weighted mean age at onset from two natural-history cohorts
      supports the timing of speech and language impairment in CLN3 disease.
- name: Cardiac conduction abnormality
  description: >
    Late in CLN3 disease, affected individuals may develop cardiac conduction
    issues including sinus node dysfunction, bradycardia, and other conduction
    abnormalities.
  phenotype_term:
    preferred_term: Cardiac manifestations
    term:
      id: HP:0031546
      label: Cardiac conduction abnormality
    onset:
      onset_category: YOUNG_ADULT
      mean_age_years: 17.8
      notes: >-
        Weighted mean age at onset across two combined CLN3 natural-history
        studies (N = 45); the second-smallest per-symptom cohort in the pooled
        13-symptom timeline, after feeding difficulties (N = 35).
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cardiac manifestations (17.8 ± 4.4,N= 45)"
    explanation: >
      Pooled weighted mean age at onset from two natural-history cohorts
      supports late-stage cardiac conduction abnormality as a CLN3 disease
      milestone.
- name: Loss of independent walking
  description: >
    Progressive motor decline culminates in loss of the ability to walk
    without assistance or daily wheelchair use, a late milestone in the CLN3
    trajectory.
  phenotype_term:
    preferred_term: Loss of independent walking
    term:
      id: HP:0002505
      label: Loss of ambulation
    onset:
      onset_category: YOUNG_ADULT
      mean_age_years: 19.5
      notes: >-
        Weighted mean age at onset across three combined CLN3 natural-history
        studies (N = 70).
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "loss of independent walking (19.5 ± 3.2,N= 70)"
    explanation: >
      Pooled weighted mean age at onset from three natural-history cohorts
      supports loss of independent walking as a late-stage CLN3 milestone.
- name: Feeding difficulties requiring enteral feeding tube
  description: >
    Feeding difficulties requiring enteral (gastric) tube feeding are a
    late-stage milestone in the CLN3 trajectory, clustering close to loss of
    independent walking and death.
  phenotype_term:
    preferred_term: Feeding difficulties requiring enteral feeding tube
    term:
      id: HP:0033454
      label: Tube feeding
    onset:
      onset_category: YOUNG_ADULT
      mean_age_years: 22.0
      notes: >-
        Weighted mean age at onset from a single CLN3 natural-history study
        (N = 35), the smallest reported per-symptom cohort in the pooled
        timeline.
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "feeding difficulties requiring enteral feeding tube (22.0 ± 1.6,N= 35)"
    explanation: >
      Pooled weighted mean age at onset from a single natural-history study
      supports enteral feeding dependence as a late CLN3 disease milestone.
treatments:
- name: Supportive care
  description: >
    No established disease-modifying therapy for CLN3 disease is modeled here.
    Management remains supportive while gene therapy and other investigational
    approaches are under study.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Currently, there is no curative therapy for this malady, and all available treatments for JNCL are symptomatic and palliative."
    explanation: >
      This CLN3/JNCL review supports supportive care as current management.
- name: Experimental AAV9-CLN3 gene therapy
  description: >
    AAV9-mediated CLN3 gene replacement is an investigational disease-targeted
    strategy supported by model data and clinical trial activity, not
    established care.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  evidence:
  - reference: PMID:37035740
    reference_title: "Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "gene replacement has emerged as a promising therapeutic platform for such disorders."
    explanation: >-
      Preclinical AAV9-CLN3 data support early gene replacement as an
      investigational therapeutic direction.
- name: Experimental TRPML1 agonist lysosomal-storage rescue
  description: >
    Pharmacological activation of the lysosomal calcium channel TRPML1
    (MCOLN1) partially reverses the CLN3 lysosomal storage phenotype in a
    human CLN3-knockout retinal pigment epithelial cell model, reducing
    storage of globotriaosylceramide and mitochondrial ATP synthase subunit c.
    The rescue is incomplete — bis(monoacylglycero)phosphate levels were not
    restored — and this is an in vitro proof-of-concept only, with no human
    data.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: CLN3 endolysosomal membrane dysfunction
    treatment_effect: INHIBITS
    description: >-
      TRPML1 activation reduces the lysosomal storage burden that defines the
      CLN3 endolysosomal storage phenotype.
  evidence:
  - reference: PMID:39080379
    reference_title: "TRPML1 activation ameliorates lysosomal phenotypes in CLN3 deficient retinal pigment epithelial cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Activation of TRPML1 reduced lysosomal storage of Gb3 and SubC"
    explanation: >
      In a human CLN3-knockout RPE cell model, TRPML1 activation reduced
      lysosomal storage of the classic CLN3 storage materials, supporting
      TRPML1 as an emerging investigational therapeutic target.
- name: Mycophenolate mofetil immunomodulation
  description: >
    Mycophenolate mofetil was tested as an immunomodulatory strategy in JNCL
    on the rationale that autoimmune/neuroinflammatory mechanisms contribute
    to disease progression. It is investigational for CLN3 disease, not
    established care.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
  evidence:
  - reference: PMID:33137890
    reference_title: "Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mycophenolate, an immunosuppressant, today is already used in the
      treatment of patients with Batten disease
    explanation: >
      This CLN3/JNCL review records mycophenolate as an immunosuppressant
      already applied in Batten disease patients.
clinical_trials:
- name: NCT03770572
  phase: PHASE_I
  status: UNKNOWN
  description: >
    Phase I/IIa open-label, single-dose, dose-escalation gene transfer trial of
    intrathecal scAAV9-CLN3 (CLN-301) in children with CLN3 Batten disease,
    evaluating safety and efficacy.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  - preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: clinicaltrials:NCT03770572
    reference_title: "Phase I/IIa Gene Transfer Clinical Trial for Juvenile Neuronal Ceroid Lipofuscinosis, Delivering the CLN3 Gene by Self-Complementary AAV9"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a phase 1/2, open-label, single dose, dose-escalation clinical
      trial to evaluate the safety and efficacy of CLN-301 (previous NCH Code:
      scAAV9.P546.CLN3) delivered intrathecally into the lumbar spinal cord
      region of subjects with CLN3 Batten disease.
    explanation: >
      ClinicalTrials.gov describes the intrathecal AAV9-CLN3 gene transfer trial
      in CLN3 Batten disease.
- name: NCT01399047
  phase: PHASE_II
  status: COMPLETED
  description: >
    Phase II randomized, placebo-controlled crossover trial of short-term
    (8-week) mycophenolate mofetil in ambulatory children with juvenile
    neuronal ceroid lipofuscinosis, assessing safety and tolerability with
    preliminary efficacy measured by the Unified Batten Disease Rating Scale.
  target_phenotypes:
  - preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT01399047
    reference_title: "Phase II, Randomized, Placebo Controlled Trial of the Safety and Tolerability of Mycophenolate in Children With Juvenile Neuronal Ceroid Lipofuscinosis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary objective of this trial is to establish the safety and
      tolerability of short-term (8 weeks) administration of mycophenolate
      mofetil in ambulatory children with JNCL.
    explanation: >
      ClinicalTrials.gov describes the randomized placebo-controlled
      mycophenolate mofetil trial in JNCL.
- name: NCT05174039
  phase: PHASE_I
  status: COMPLETED
  description: >
    Open-label phase I/II safety, pharmacokinetic, and efficacy study of oral
    miglustat (substrate reduction therapy) in approximately 6 patients aged
    17 years and older with CLN3 disease over 104 weeks. Recorded as PHASE_I
    because the schema has no combined phase I/II value.
  target_phenotypes:
  - preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: clinicaltrials:NCT05174039
    reference_title: "An Open-label Safety, Pharmacokinetic, and Efficacy Study of the Combination of Miglustat for the Treatment of CLN3 Disease in Patients 17 Years of Age and Older"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is an open label study in approximately 6 subjects in 2 centers to
      assess the safety, PK, and efficacy of the maximum tolerable dose (MTD)
      of oral miglustat
    explanation: >
      ClinicalTrials.gov describes the open-label miglustat study in adult and
      adolescent CLN3 disease.
- name: NCT04637282
  phase: PHASE_III
  status: NOT_RECRUITING
  description: >
    Randomized, multicenter, double-blind, placebo-controlled phase III study
    of PLX-200 (a gemfibrozil formulation, proposed to act via PPAR-alpha/TFEB
    induction of lysosomal biogenesis) in participants with mild-to-moderate
    CLN3 disease. Listed on ClinicalTrials.gov as not yet recruiting, recorded
    here as NOT_RECRUITING since the schema has no NOT_YET_RECRUITING value.
  target_phenotypes:
  - preferred_term: Motor deterioration
    term:
      id: HP:0002333
      label: Motor deterioration
  - preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: clinicaltrials:NCT04637282
    reference_title: "A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The purpose of this study is to evaluate the safety and efficacy of
      multiple doses of PLX-200 in patients with CLN3 disease.
    explanation: >
      ClinicalTrials.gov describes the placebo-controlled PLX-200 efficacy
      study in CLN3 disease.
discussions:
- discussion_id: gap_cln3_standardized_natural_history_data
  prompt: >-
    Despite two decades of CLN3 natural-history research, why does a clear,
    globally standardised timeline of symptom onset and progression remain
    poorly defined, and what would resolve it?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - progression#Late multisystem decline and mortality
  rationale: >-
    The pooled 13-symptom timeline in PMID:41501856 is the largest available
    natural-history summary for CLN3 disease, but it is a retrospective
    meta-analysis across nine heterogeneous studies with per-symptom N ranging
    from 35 to 254 (not a single prospective cohort), and ages are age at
    reported (not biological) onset. The four interventional trials already
    recorded on this entry (NCT03770572, NCT01399047, NCT05174039,
    NCT04637282) need exactly this kind of quantified natural-history timeline
    for external comparators and endpoint selection, which is why the
    remaining lack of standardised, prospective, longitudinal data collection
    is a live gap rather than a purely historical one.
  evidence:
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite two decades of natural history research, a clear timeline of CLN3 disease symptom onset and progression remains poorly defined, limiting optimal patient management and therapeutic development."
    explanation: >
      The paper's own background frames the absence of a clear, standardised
      CLN3 natural-history timeline as an unresolved limitation on patient
      management and therapeutic development.
  - reference: PMID:41501856
    reference_title: "A timeline of symptom onset and disease progression in CLN3 disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the critical importance of collecting globally standardised, quantifiable, longitudinal data for optimising patient management and advancing therapeutic approaches for CLN3 disease."
    explanation: >
      The paper's conclusion explicitly calls for globally standardised,
      quantifiable, longitudinal natural-history data collection as the path
      to resolving this gap.
notes: >-
  PMID:41501856 pooled nine CLN3 natural-history studies (423 patients, ages
  4-39 years) to derive weighted mean ages at onset for 13 core symptoms via a
  literature-review meta-analysis, not a single prospective cohort. Nine
  studies were screened in, but each symptom's weighted mean derives from only
  one to four of them, so a per-symptom figure is never backed by all nine.
  Per-symptom N ranges widely (35 to 254), so confidence is uneven; the
  latest milestones (cardiac manifestations N = 45, enteral feeding N = 35)
  rest on especially small subsets. Reported ages are age at *reported* onset,
  inheriting ascertainment and diagnostic-delay bias from the source cohorts —
  consistent with this entry's existing PMID:31926949 evidence on delayed
  diagnosis and ophthalmic masquerades — so these figures are best read as
  "age at clinical recognition" rather than biological onset. Sleep
  disturbance carries a weighted SD (±6.1) wider than the mean-to-mean spacing
  of most of the timeline and was reported by only one of the nine studies, so
  its position in the sequence should not be over-read; the same single-study
  caveat applies to Parkinsonian gait and to feeding difficulties.